Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in Ireland

Alimera Sciences announced that Alimera Sciences Europe, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis affecting the posterior segment in Ireland. Reimbursement was granted by the Health Service Executive Corporate Pharmaceutical Unit and National Centre for Pharmacoeconomics in Ireland in line with its label in Europe.

“We continue to expand the availability of our noninfectious uveitis indication in our international segment with it now accessible to patients in all of our direct markets in addition to our key distributor markets,” Rick Eiswirth, President and Chief Executive Officer of Alimera, said in a company news release. “We are excited to make Iluvien available for patients suffering from this persistent inflammatory condition and give physicians in these countries a better tool to help their patients see better, longer, with fewer injections.”

The Iluvien sustained-release intravitreal implant is indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and for prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIU-PS).